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Abstract
Genetic and epigenetic changes deregulate RNA and protein expression in cancer cells. In this regard, tumors
exhibit an abnormal proteome in comparison to the corresponding normal tissues. Translation control is a crucial
step in the regulation of gene expression regulation under normal and pathological conditions that ultimately
determines cellular fate. In this context, evidence shows that transfer and ribosomal RNA (tRNA and rRNA)
modifications affect the efficacy and fidelity of translation. The number of RNA modifications increases with the
complexity of organisms, suggesting an evolutionary diversification of the possibilities for fine-tuning the functions
of coding and non-coding RNAs. In this review, we focus on alterations of modifications of transfer and ribosomal
RNA that affect translation in human cancer. This variation in the RNA modification status can be the result of
altered modifier expression (writers, readers or erasers), but also due to components of the machineries (C/D or H/
ACA boxes) or alterations of proteins involved in modifier expression. Broadening our understanding of the
mechanisms by which site-specific modifications modulate ribosome activity in the context of tumorigenesis will
enable us to enrich our knowledge about how ribosomes can influence cell fate and form the basis of new
therapeutic opportunities.
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Introduction
Nucleotide modifications arise in most classes of RNA
and more than 160 modifications are known [1]. Initial
genetic studies in yeast and E. coli demonstrated that
rRNA modifications play an important role in ribosome
function [2–4], supported by further research in the area
in the early 2000s [5]. Thenceforth, various ribosomal
and transfer RNA modifications have been found to par-
ticipate in determining cellular fate in cancer [6, 7]. For
rRNA, modifications usually have an effect on early
biogenesis steps, but the catalytic function of the ribo-
some in translation can also be subtly modulated by spe-
cific posttranscriptional modifications and selectively
translate certain types of messenger RNA [8], such as
the case for the rRNA methyltransferase NSUN5 [9].
Nevertheless, translational changes in the context of hu-
man cancer have been poorly studied, with most of the
studies done describing how the expression of RNA
modifiers could inform patient diagnosis or prognosis
[10–14]. This lack of research can be explained in part
by the great investment in effort and resources required
to undertake a thorough study of an rRNA or tRNA
modification —from cellular model construction and
validation, through RNA-sequencing to visualize the
transcriptome, to ribosome profiling and SILAC— in
order to appreciate the differential translational
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efficiency of specific messengers, also known as transla-
tomics [15]. In parallel, other methods are used to evalu-
ate global protein synthesis, including the O-propargyl-
puromycin assay and isotope pulse labeling with S35-
labeled amino acid [16].
Alterations in the expression levels of few RNA modi-
fiers of tRNA and rRNA have been linked to cancer as
well as other human diseases [17–20]. However, the
consequences of changes affecting the core machinery of
protein translation are rarely explained. In the context of
human cancer, after a brief description of the type of
RNA and the machineries involved, we summarize the
modifications that have been functionally characterized
(Fig. 1; Tables 1 and 2). We also discuss which paths
look promising in cancer therapy and provide a perspec-
tive on the possibilities for further deciphering the com-
plex language of RNA modifications.
Ribosomal RNA
The ribosome is a complex system that translates the nucleo-
tide code of messenger RNA into protein in cells. In humans,
this complex machinery comprises four ribosomal RNAs
(the 28S, 18S, 5.8S and 5S rRNAs) that are synthesized by
polymerases I and III, and 80 ribosomal proteins (RPs) tran-
scribed by polymerase II [46], all of which are organized in a
large 60S subunit and a small 40S subunit. From the tran-
scription of the ribosomal DNA to the final export into the
cytoplasm, ribosome biogenesis involves more than 400 pro-
teins and small nucleolar RNAs (snoRNAs) [47]. Ribosome
heterogeneity is the result of various changes including those
in the diversity of the composition of RPs and RPs mutations,
abnormalities in rRNA modifications during ribosomal
biogenesis, and those due to specific endogenous or exogen-
ous factors. This heterogeneity, which also appears between
cell types, has been thoroughly reviewed by Maria Barna and
colleagues [48, 49]. Changes in posttranscriptional modifica-
tions of rRNAs can influence translational fidelity, leading to
nonsense suppressions or amino acid misincorporations, and
modifying the preferential mode of translation initiation (i.e.,
CAP versus internal ribosome entry site (IRES)) of key can-
cer genes [50, 51]. Finally, a defect in rRNA posttranscrip-
tional modifications may cause specific clinical syndromes
and may be associated with a higher incidence of cancer,
which is the case for DKC1 mutation related to X-linked dys-
keratosis congenita (X-DC), and for Dyskerin overexpressed
in prostate cancer [52–55].
2′-O-methylation (Nm) machinery and implications for
human cancer
The association of snoRNAs in human cancer and their
potential role in cancer diagnosis and therapy has recently
Fig. 1 Positions of the various RNA modifications implicated in translation in human cancer in a the ribosome structure and b the transfer RNA.
Structures were designed with PyMOL using 4UG0 and 5WWT identifiers from PDB
Table 1 Modifications of ribosomal RNA that affect translation
in human cancer
Modification Modifier Cancer References
Nm Fibrillarin Breast cancer [21, 22]




Ψ Dyskerin Pituitary adenoma, breast cancer [25, 26]
Ψ SNORA24 Hepatocellular carcinoma [27]
m6A ZCCHC4 Hepatocellular carcinoma [28]
m5C NSUN5 Glioma [9]
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been reviewed [56]. The RNA component of the 2′-O-
methylation machinery is a C/D box snoRNA, an evolu-
tionarily conserved noncoding small (70–120 nucleotide-
long) nucleolar RNA [57]. The assembly and composition
of C/D snoRNP complexes have been extensively reviewed
[5, 19, 58], and are simply summarized here. C/D box
snoRNAs catalyze the methylation of ribose residues (2′-
O-methylation) and can affect every type of nucleotide (A;
U; C; G and pseudouridine). It contains two short con-
served sequence motifs (named C and D), located near the
5′ and 3′ ends of the snoRNA, respectively, and present
in duplicate (C′ and D’). It is the most abundant rRNA
modification in eukaryotes, with two, 42 and 68 sites
modified in the 5.8S, 18S and 28S subunits, respectively
[59]. The complex involves the methyltransferase fibril-
larin (FBL), an RNA-binding protein 15.5 K (NHP2L1),
and a heterodimer of two closely related proteins, NOP56
and NOP58. This complex is named C/D box snoRNP
(SNORD). Modification of the expression of the different
factors involved can directly influence the methylation sta-
tus of the corresponding ribose.
High levels of fibrillarin (FBL) are accompanied by
modifications of the rRNA methylation pattern, im-
pairment of translational fidelity, and an increase of
internal ribosome entry site (IRES)-dependent trans-
lation initiation of key cancer genes [21]. Indeed,
FBL is overexpressed in prostatic neoplasia [60] and
breast cancer [21, 22]. It was demonstrated that FBL
expression correlates with RNA polymerase I tran-
scriptional activity and production of ribosomal
RNA, and is inversely correlated with cancer-cell
doubling time [61].
Chronologically, the role of 2′-O-methylation in regu-
lating the translation of selected mRNAs was first dem-
onstrated through the observation of associations
between altered 2′-O-methylation profiles and transla-
tion vector reporter assays in breast cancer models [21,
62] and subsequently in models in which expression of
FBL was knocked down [21, 22, 50, 63].
In 2009, Belin and colleagues [62] observed that breast
cancer cells with increased aggressiveness displayed non-
modified global translational activity but had IRES-
initiated translation, notably that of p53 mRNA, which
was less efficient. They also noted that control of trans-
lational fidelity was substantially reduced. This suggests
that this aggressive phenotype is associated with pro-
found alterations of ribosomal control, leading to poorer
quality control of translation in cancer cells.
The expression of FBL gene is decreased by the direct
binding of the tumor suppressor transcription factor
p53. In human mammary epithelial cells, the diminution
or suppression of p53 expression leads to modifications
in the rRNA methylation pattern at the single nucleotide
level, impairment of translational fidelity, and increased
IRES-dependent translation of key cancer-related genes,
such as IGF-1R, C-MYC, VEGF-A, and FGF1/2 [21]. As
TP53 is frequently mutated in cancer, the authors
showed that the level of FBL is significantly higher in
mutated breast cancer than in wild type cells. They ob-
tained the same results in a retrospective statistical ana-
lysis. Specifically, the authors showed that the rRNA
methylation pattern at 18 sites distributed along the
rRNAs in functionally important domains were altered
in cells with p53 knockdown, increasing the rRNA
methylation status due to the increased expression of
FBL. Functionally, the p53-mediated increase of FBL ex-
pression leads to an increased bypass of a premature
stop-codon and the misincorporation of amino acids,
demonstrating the combinatory roles of p53 and FBL in
translational quality control. IRES-dependent translation
was stronger, whereas the CAP-dependent mechanism
showed no significant differences. The complementary
experiment directly modulating FBL expression con-
firmed that the efficacy of IRES-dependent translation
Table 2 Modifications of transfer RNA that affect translation in human cancer
Modification Modifier tRNA localization Cancer References
m5C NSUN2 Cytosol & Mitochondria Breast cancer [29–33]




Cytosol Hepatocellular carcinoma [34–36]





i6A TRIT1 Cytosol & Mitochondria Lung adenocarcinoma [43]
Q QTRT1/2 Cytosol & Mitochondria Lymphoma and leukemia [44, 45]
Lung cancer
Ovarian carcinoma
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initiation is driven by rRNA methylation. Clinically, the
same authors have shown that FBL overexpression is as-
sociated with tumorigenesis and poor survival in patients
with breast cancer and promotes cellular proliferation
and resistance to doxorubicin chemotherapy of MCF7
breast cancer cells [21].
Thereafter, Su and colleagues found that FBL increased
expression in association with an increasing abundance of
a cluster of snoRNAs. The decrease of FBL had an anti-
tumorigenic effect in vitro and in vivo, demonstrating the
importance of the controlled regulation of rRNA modifi-
cations [22]. Complementary to the study of Marcel et al.
[21], they revealed that FBL overexpression suppresses the
p53 response to stress. As p53 mutation is relatively un-
common in breast cancer (around 20% of cases), this
mechanism of FBL overexpression/p53 stress response
suppression is thought to be an alternative option for p53
inactivation [22]. First, the authors showed that p53 pro-
tein stability was increased upon FBL knockdown and p53
mRNAs were enriched in polysomal fractions in these
cells. They found that the level of IRES translation of p53
and other transcripts was significantly higher in FBL
knockdown cells and that this mechanism is driven by the
IRES trans-acting factor PTB in the context of nucleolar
stress [22].
More recently, in 2017, Erales et al. characterized 2′-
O-methylation in HeLa cells using a RiboMethSeq ap-
proach to quantitatively and qualitatively determine the
modulation of the methylation pattern when FBL is
knocked down [63]. Upon FBL knockdown, the fre-
quency of 2′-O-methylation decreased at almost all sites,
but not statistically significantly for all of them, and with
differences among sites indicating site-specific regulation
of 2′-O-methylation by FBL. Structurally, the affected
sites were distributed throughout the ribosome struc-
ture, including functionally important regions like the A
and P sites, the intersubunit bridges and the peptide exit
tunnel, but in contrast, methylation sites close to the
PTC and the decoding center within 18S rRNA were not
affected. FBL knockdown reduced global protein synthe-
sis, as shown by puromycylation assay and isotope pulse
labeling with [35S]-labeled amino acids. At the mRNA-
specific translational level, the authors used ribosome
profiling of HeLa cells expressing an inducible FBL
shRNA or control shRNA. They identified few transla-
tionally altered genes upon FBL knockdown [63]. Using
a bicistronic reporter, they saw that knockdown of FBL
induced a decrease in IRES-dependent translational initi-
ation of FGF1, IGF-1R and the type II encephalomyocar-
ditis virus (EMCV) IRES, but not of VEGFA IRES.
Luciferase activity/mRNA ratios, which give an indica-
tion of the translation efficiency, showed a decrease in
CAP-dependent translation, and a stronger decrease in
the IRES-dependent one.
Fibrillarin affects ribosomal RNA 2′-O-methylation al-
most globally. Nevertheless, a few studies have identified
particular snoRNA C/D boxes as site-specific writers
with translational consequences in human cancer.
SNORD50 methylates rRNA at positions 28S-C2848
and 28S-G2863 in humans. Variation in SNORD50 ex-
pression has been observed in colon cancer, breast car-
cinoma, prostate cancer and, finally, B-cell lymphoma.
Historically, the SNORD50 host gene was found by Ta-
naka in 2000 at a chromosome breakpoint in a human
B-cell lymphoma [64]. Further studies have demon-
strated an association between SNORD50 and clinical
outcomes [65–67].
Regarding colon cancer, Pacilli and colleagues in 2013
studied the expression of SNORD50 in cell lines and tu-
mors. They found that the level of SNORD50 expression
was lower in tumors compared with normal counter-
parts, the difference being significant in a subgroup of
low-stage tumors. They also found a significant associ-
ation between the level of SNORD50 expression and
tumor stage [23]. Notably, they showed that SNORD50
expression is inversely correlated with cellular prolifera-
tion, highlighting the fact that ribosome biogenesis re-
quires rRNA modifications as part of the process. The
overexpression of SNORD50 in HTC116 successfully in-
creases both SNORD50 and C2848 methylation. They ob-
served a general decrease in CAP-dependent translation
and an increase in IRES-dependent translation for three
IRESs: CrPV, HCV, and c-Myc, while EMCV IRES transla-
tion was not affected by changes in the methylation of this
specific site [23]. Interestingly, the literature suggests that
SNORD50 expression is inversely correlated with cellular
proliferation and tumor progression, results that are not
fully consistent with the oncogenic role fibrillarin and
methylation activity play in tumors. Thus, it is possible
that it is not the increase of methylation, but the aberrant
2′-o-methylation of specific positions which may be asso-
ciated to different oncogenic effects.
In 2016, Zhou et al., studied an underlying mechanism
of self-renewal that drives leukemogenesis. This study is
an excellent example of workflow characterizing epitran-
scriptomic modifications in human malignancies. The
authors identified a pathway that links the chimeric
oncogene protein AML1-ETO to enhanced snoRNA
functions via the amino-terminal enhancer of split (AES)
and DDX21 interaction [24]. They showed that deletion
of two snoRNAs (SNORD14D, which methylates the
18S-C462 site, and SNORD35A, which methylates the
28S-C4506 site close to the PTC) suppresses the clono-
genic potential of leukemia cells in vitro and delayed
leukemogenesis in vivo. Briefly, they demonstrated that
AES is essential for AML1-ETO-induced self-renewal of
leukemia cells in vitro and in vivo. Also in the AML1-
ETO cells, snoRNAs were decreased by AES
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suppression. Indeed, microarray-based gene expression
profiling in a comparison of fetal liver cells overexpress-
ing AML1-ETO from mice wild-type (WT) for AES
(Aes+/+) or Knockout (KO) (Aes f/f) revealed that 20 of
the top 100 candidates were snoRNAs, all of which were
severely reduced following AES deletion, and preferen-
tially C/D box snoRNAs. Conversely, forced expression
of AES in fetal liver cells induced snoRNA expression.
At this point, they mapped the pseudouridylation to
evaluate the impact of AES in rRNA modification and
AES depletion weakly affected pseudouridylation in
these cells. However, two 2′-O-methylation sites guided
by SNORD43 and SNORD32A (methylating 18S-C1703
and 18S-G1328, respectively) showed decreased methy-
lation. In line with a decrease in snoRNA expression, cell
size was also significantly smaller in AES KO compared
with WT. In AML1-ETO-induced expression cells with
AES KO and a shRNA AES knockdown cell model, OP-
Puro incorporation was significantly reduced, revealing a
reduction in translation efficiency following AES deple-
tion in AML1-ETO-transduced cells [24]. Depletion of
NOP58 (a component of the C/D box complex) reduced
C/D box snoRNA levels and rRNA methylation. More-
over, the colony formation of various leukemia cell lines
was significantly reduced, suggesting a crucial role for
rRNA 2′-O-methylation in clonogenicity. Knocking out
six SNORDs showed that reduced levels of expression of
SNORD34, SNORD35A and SNORD43 impaired clono-
genic growth in the cell model, and curiously, depletion
of SNORD14D reduced colony formation without affect-
ing 18S-C762 methylation. Depletion of SNORD14D,
SNORD34 (which methylates 28S-U2824), SNORD35 or
SNORD43 resulted in a reduction of cell size and pro-
tein synthesis. In the context of AML1-ETO, knockout
of SNORD14D or SNORD35A reduced colony forma-
tion in MV4–11 cells and delayed leukemogenesis in im-
munodeficient NSG mice. These results indicate that
different snoRNAs have distinct roles and that some of
them are important for leukemogenesis beyond AML1-
ETO-induced leukemia. As expected, fibrillarin overex-
pression in AES-knocked-down cells increased 2′-O-
methylation at various sites and promoted ribosome ac-
tivity, implying that the functions of AES in AML1-ETO
cells depend on both snoRNA regulation and rRNA
methylation. These results are consistent with the onco-
genic role fibrillarin plays in solid tumors [24].
Pseudouridylation (Ψ) machinery and implications for
human cancer
Pseudouridylation is the most common modification in
RNA and the second modification found in rRNA after
2′-O-methylation. There are approximately 106 pseu-
douridines in rRNA clustered close to functionally im-
portant sites [59]. These modifications are driven by a
snoRNA H/ACA box or by a pseudouridine synthase
(PSU). PSUs recognize substrate and catalyze the isom-
erization reaction of uridine to pseudouridine without
using any cofactors. They are classified into six families
[68]. The catalytic center involves aspartate as the nu-
cleophile for all PSUs, even in cases where the mechan-
ism of isomerization is poorly understood [68].
RNA-dependent pseudouridylation involves an H/
ACA box RNA that complexes with a set of proteins.
Box H/ACA RNAs are noncoding RNAs that fold into a
hairpin–hinge–hairpin–tail secondary structure. The
hinge and tail regions contain evolutionarily conserved
box H with the consensus sequence “ANANNA” (N for
any type of nucleotide) and the trinucleotide Box “ACA,
” respectively. The two hairpins contain an internal loop
known as the pseudouridylation guide pocket, which has
a short specific sequence complementary to the sub-
strate RNA. The guiding pockets recognize the sites of
modifications through Watson–Crick base-pairing inter-
actions with substrate RNAs, thereby positioning the
uridine to be modified at the base of the upper stem and
leaving it unpaired. This brings the target site between
13 and 16 nucleotides upstream of either box H or box
ACA [69, 70]. The core proteins are dyskerin (encoded
by DKC1 gene), glycine–arginine-rich protein 1 (GAR1),
non-histone protein 2 (NHP2), and nucleolar protein 10
(NOP10) [69, 71]. Dyskerin is the protein that exhibits
the enzymatic activity within this complex, which is
known as H/ACA snoRNP. This enzyme has two dis-
tinct functions: the pseudouridylation necessary for
rRNA processing, and the stabilization of the telomerase
RNA component that is essential for telomerase activity.
Similar to fibrillarin for C/D box RNPs, DKC1 or dys-
kerin regulation affects its rRNA epitranscriptomic activ-
ity. In 1998, Heiss et al. identified the mutation
responsible for X-linked recessive dyskeratosis congenita
in a gene named XAP101 [52]. This disease is character-
ized by bone marrow failure, skin abnormalities, and an
increased susceptibility to develop cancer [72]. Pseu-
douridylation is thought to play a role in translation,
modulating the interactions between tRNA, rRNA and
mRNA. The influence of modified nucleosides on the
local structure of the antisense loop is essential for the
proper binding of tRNA to the ribosome [73]. Mainten-
ance of the proper conformation of the three anticodon
residues helps foster correct codon–anticodon interac-
tions. This may increase translational accuracy by redu-
cing the rate of peptide bond formation, thereby
allowing more time to reject incorrect codon–anticodon
pairs [73].
In 2006, Montanaro and colleagues showed that, in
human breast cancer, low levels of expression of dys-
kerin, as determined by immunohistochemistry and RT-
PCR, were associated with a better outcome [74]. The
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same year, Yoon et al. were the first to report the influence
of dyskerin expression on translation, although this time it
occurred in X-linked dyskeratosis congenita (X-DC) [75].
Using a knocked-in DKC1 point-mutation mouse model,
they saw that reduced rRNA pseudouridylation did not
affect total protein synthesis. They then analyzed the
translationally active ribosome-associated mRNAs from
steady state and activated primary splenic lymphocytes,
one of the hematopoietic lineages affected in X-DC. They
identified three out of 1500 mRNAs whose expression was
specifically decreased in polysome-associated fractions for
DKC1m lymphocytes: the p27 tumor suppressor, the anti-
apoptotic proteins XIAP (X-linked Inhibitor of Apoptosis
Protein), both of which harbor IRES elements, and Bcl-xL
showed a significant decrease in their association with
polysomes in DKC1m cells compared with wild-type cells
[75]. The decrease was observed only at the protein level,
where a specific translation in DKC1 cells was revealed.
Yoon et al. confirmed IRES-dependent translation of p27
and XIAP and also established that BCL-XL contains a
previously unreported IRES element. In 2010, the same
group, headed by Davide Ruggero, showed that DKC1 is
mutated in pituitary adenoma and that this genotype
causes a defect in pseudouridylation activity and reduced
expression of p27 [25]. They observed that this translation
was reduced in the pituitary of DKC1m mice. DKC1m/
p27+/− mice developed a similar pituitary malignancy to
that of p27−/− mice. Finally, they found a DKC1 mutation
in patients with pituitary adenoma that drastically reduced
DKC1 expression and pseudouridylation, but also brought
about a reduction in p27 expression. Therefore, DKC1 is a
tumor suppressor that controls translation by its direct
role in rRNA modifications [25]. In parallel, they also
established that p53 IRES-dependent translation is im-
paired in DCK1m cells during oncogene-induced senes-
cence in X-DC [76]. Normally, during this senescence
transition, IRES translation is facilitated, promoting the
translation of p53. This mechanism in X-DC is close to
that controlling fibrillarin overexpression, which inhibits
p53 expression [21]. In 2013, Rocchi et al. found that
angiogenesis in human breast epithelial cells was pro-
moted by enhanced VEGF-IRES-mediated translation as-
sociated to the lack of dyskerin [26].
A H/ACA box RNP has been identified as playing a
role in tumorigenesis by regulating translation. A recent
study by McMahon and colleagues has shown the regu-
lation of SNORA24 in human hepatocellular carcinoma
and its collaboration with RAS mutation to promote
cancer [27]. SNORA24 drives two pseudouridylations
in the 18S rRNA at positions 609 and 863. Ribosomes
lacking the corresponding modifications exhibited per-
turbations in the aminoacyl-transfer RNA (aa-tRNA)
selection and altered pre-translocation ribosome com-
plex dynamics [27].
Further research is needed to fully understand the
interplay between genetic alterations, regulation of epi-
transcriptomics and translation in human tumorigenesis.
Other modifications of ribosomal RNA affecting
translation in human cancer
Only two recent studies have identified other types of
rRNA modification impairment that influence transla-
tion in human cancer.
The first, by Ma and colleagues in 2018, identified the
N6-methyladenosine ZCCHC4 as being responsible for
modifying the rRNA at position 4220, and this methyl-
transferase is overexpressed in human hepatocellular
carcinoma [28]. This position is not in a functionally im-
portant region but, as seen before, changes in translation
are not linked to changes of modifications in these re-
gions. Using a luciferase reporter and then l-
homopropargylglycine-derived metabolic labeling of
newly synthesized proteins, the authors showed that
ZCCHC4 KO in hepG2 cells displayed a lower level of
global translation than in WT. After a sucrose density
gradient and polysome-associated mRNA sequencing,
they suggested that loss of m6A methylation should re-
sult in a reduction of the tight control of translation in
mRNA populations, and might increase the translation
of a subset of mRNAs. Finally, gene ontology indicated
that genes affected by ZCCHC4 are involved in mem-
brane protein targeting, the mRNA catabolic process, ER
localization, and translation initiation. We recently stud-
ied the role of NSUN5, an m5C methyltransferase, in hu-
man gliomagenesis [9]. NSUN5 methylates the rRNA at
position 28S-C3761 (old nomenclature 3782) and influ-
ences global translation, since, under conditions of
stress, reduced OP-puro and H3-leucine incorporations
were observed in cell lines depleted in NSUN5 [9]. This
condition also leads to a specific translation in response
to stress, as determined for some proteins regulated only
at the translational level. We chose to validate NQO1 as
a relevant candidate for therapeutic targeting [9].
Other rRNA modifiers have been linked to human
cancer, but the underlying mechanisms driving transla-
tional change require further investigation. NAT10, for
example, is a N-acetyltransferase involved in histone and
microtubule modification, pre-rRNA processing, but also
in the acetylation of rRNA at positions C1337 and
C1842, and the acetylation of leucine/serine tRNA [77,
78]. NAT10 has been found upregulated in hepatocellu-
lar carcinoma (HCC) [79], ovarian cancer [80] and AML
[13], and correlates with poor survival of patients. This
upregulation also promotes metastasis of HCC cells [81,
82]. Also, sub-cellular redistribution of NAT10 in colo-
rectal cancer is able to promote cell motility through
modifying cytoskeleton dynamics [83]. Another modifier,
NOP2 (also named NSUN1 or p120), a probable rRNA
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methyltransferase for position C4447 of the human 28S
RNA [84], has been described as overexpressed in lung
adenocarcinoma [14, 85]. In HCC, Wang and colleagues
have described that LncRNA-hPVT1 stabilizes NOP2,
thereby increasing cell cycle rate, and promoting both
cell proliferation and the acquisition of stem cell-like
properties [86]. The cytosine methylated by NOP2 is
part of the A-loop of the peptidyl transferase center.
This is a critical position within an area responsible for
the initial interaction with the incoming peptidyl-tRNAs,
as well as the presentation of tRNAs in the correct con-
formation for the optimal peptidyl transfer reaction [84].
This mechanism could have major impact on protein
synthesis in cancer cells with NOP2 expression changes.
Overall, the role of rRNA modifications in the tumori-
genic mechanisms driven by these two modifiers will
need further investigation.
In summary, few studies have clearly identified
changes in translation in human cancer, but there are
enough of them to reveal the importance of this regula-
tion in human tumorigenesis (Fig. 1a; Table 1).
Transfer RNA
Transfer RNAs are small RNAs that carry amino acids
to ribosomes that translate an mRNA. This allows amino
acid incorporation into the synthesized peptide accord-
ing to the corresponding codon. In humans, tRNAs can
carry up to 21 different amino acids. tRNAs present five
functional arms or loops. The aminoacylation arm is
where the aminoacyl synthase incorporates the corre-
sponding amino acid, whereas the anticodon loop is the
region containing the three nucleosides that pair with
the mRNA codon. There are also the D-loop, so called
because of the dihydrouridines it contains, the T-loop
for the conserved TψC sequence, and the variable arm,
whose length differs in each tRNA [87].
tRNAs are synthesized by RNA polymerase III and all
pre-tRNAs undergo 5′ and 3′ end processing, and
addition of CCA to the processed 3′ end. Some tRNAs
also require intron cleavage and subsequent ligation.
tRNA biogenesis occurs in the nucleus and mitochon-
dria, depending where they are codified. Those that are
synthesized in the nucleus are exported to the cytoplasm
as a final step [88, 89]. Aminoacylation is the covalent
attachment of amino acids to their corresponding tRNA,
the reaction being catalyzed by aminoacyl-tRNA synthe-
tases. There is at least one enzyme for each amino acid,
and they can function in the cytoplasm, the mitochon-
dria, or in both locations [90]. Throughout this process,
tRNA can undergo nucleoside modifications, some of
which are introduced into all tRNAs, whereas others are
tRNA-specific. Modifications can also vary between
cytoplasmic and mitochondrial tRNA.
RNA polymerase III, aminoacyl-tRNA synthetases and
other proteins involved in tRNA maturation steps are
known to be altered in a wide range of tumors. This can
be explained by the need for tRNA availability and trans-
lation efficiency to supply the higher level of protein syn-
thesis that occurs in cancer cells [91, 92].
During different steps of their maturation, modifica-
tions are anchored to tRNA, allowing the correct folding
of their secondary (cloverleaf) and tertiary (L-shaped)
structures through correct base-pairing, codon recogni-
tion and binding. These ensure the fidelity of translation,
structural stability and integrity [29, 37, 93]. Distur-
bances in the regulation of these steps can create oppor-
tunities for cancer to arise.
Transfer RNA modifications in human cancer
5-methylcytidine (m5C)
5-methylcytidine is incorporated at different positions of
tRNA by NSUN2, NSUN3, NSUN6, and TRDMT1.
NSUN2 and TRDMT1 are the best functionally char-
acterized epitranscriptomic enzymes. TRDMT1 methyla-
tion prevents tRNA cleavage [94, 95]. tRNA fragment
accumulation and loss of cytosine-5 methylation in
tRNAs was associated to decreased ribosome density in
mRNAs and increased ribosome density in 5′ UTRs
[96]. In mice, methylation also confers stability to their
tRNA substrates as loss of 5-methylcytidine causes tRNA
degradation, and loss of Trdmt1 and Nsun2 leads to a
global decrease of protein synthesis [29]. Upregulation of
NSUN2 expression was identified in one-third of pri-
mary breast tumors and breast cancer cell lines. Also,
high levels of NSUN2 expression were detected in head
and neck carcinoma. In these studies, this aberrant ex-
pression significantly increases mortality [30–32]. More-
over, the oncogene RLP6 has been found to partially
regulate NSUN2 translation and so tumorigenesis func-
tion in human gallbladder carcinoma [33].
m7G
METTL1 and WDR4 are both necessary for the introduc-
tion of the 7-methylguanosine at position 46 [34]. In 2018,
Lin et al. have reported that METTL1 knockdown reduces
the m7G fraction, which causes tRNA destabilization and
ribosome pausing at m7G tRNA-dependent codons that
leads to a decrease in translation [35]. Overexpression of
METTL1 in hepatocellular carcinoma has been shown to
promote cell proliferation and migration, and to lead to
poor prognosis in HCC [36].
mcm5U
5-methoxycarbonylmethyluridine (mcm5U) is a common
modification in the wobble position. ALKBH8, with
TRM112 as a partner, catalyzes the methylation of 5-
carboxymethyluridine (cm5U) to mcm5U [37, 38].
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tRNASec is one of the targets of ALKBH8, this tRNA
transfers the amino acid selenocysteine during seleno-
protein translation. A large number of selenoproteins
are involved in the detoxification of ROS. It has been
shown that ALKBH8 deficiency causes a decrease in
selenocysteine protein translation and consequently ROS
stress that triggers oxidative DNA damage [38, 97]. It
has been reported both in vitro and in vivo that
ALKBH8 promotes the expansion, survival and invasion
of bladder cancer [39, 98]. Cancer cells use AKBH8 ex-
pression as an antioxidant system against the ROS stress
generated during tumorigenic transformation [97].
Msm5U is necessary for the formation of some deriva-
tives, such as 5-methoxycarbonylmethyl-2-thiouridine
(mcm5s2U). CTU1, CTU2 and ELP3 are the thiolation
effectors with URM1 as the sulfur donor [37, 40, 99].
The mcm5s2U complex is heavily implicated in cancer.
On one hand, its enzymes levels have been detected at
higher levels in human tumor biopsies and in cultured
melanoma cells with BRAFV600E mutation. An in silico
analysis revealed that this kind of melanoma also has
high levels of hypoxia-induced factor 1α (HIF1α), which
is known for its involvement in tumorigenesis progres-
sion. The mRNA sequence of HIF1α is rich in U34 co-
dons that require tRNA modification for correct
translation. Thus, U34-related enzyme overexpression
triggers increased HIF1α translation and thereby cancer
transformation [41]. Similarly, U34-related enzymes
were found to be overexpressed in breast cancer pa-
tients. The IRES trans-acting factor (ITAF) protein DEK
has U34 codon-dependent translation regulation. DEK
promotes the translation through the IRES sequence of
LEF1, whose expression is associated with a higher risk
of metastases [42].
Isopentenyladenosine (i6A)
TRIT1 introduces a dimethylallyl pyrophosphate at pos-
ition 37, generating an isopentenylated adenosine in
both cytoplasmic and mitochondrial tRNA [100–102]. In
particular, it has been related to selenoprotein expres-
sion since tRNASec is one of its targets [103]. Expression
of some selenoproteins are influenced by TRIT1 deple-
tion [43]. Spinola et al. observed downregulation of
TRIT1 expression in lung adenocarcinoma patients and
noted that expression of TRIT1 in a lung adenocarcin-
oma cell line diminishes tumorigenesis. Its tumor sup-
pressor effect is indicated by the role of some
selenoproteins in diminishing oxidative stress [104].
However, as demonstrated in the case of ALKBH8,
which modifies mcm5U34, cancer can also use seleno-
proteins to maintain oxidative stress at sublethal levels.




mino)methyl)-7-deazaguanosine) is a derivative of the 7-
deazagunine located in the wobble position. This modifi-
cation is introduced by the tRNA-guanine transglycosy-
lase (TGT) heterodimer formed by QTRT1 (catalytic
subunit) and QTRT2 [44]. Eukaryotes cannot synthesize
queuine but they obtain it from gut microbes or food.
Tuorto et al. suggested that G34-containing tRNAs
cause a translational delay that induces an accumulation
of misfolded proteins and hence, endoplasmic reticulum
stress and an unfolded protein response. In order to
avoid this situation, Q modification prevents the elong-
ation from slowing down [105]. Reduced Q content has
been detected in a wide range of cancers [45].
This overview of the modifications affecting transfer
RNAs (Fig. 1b; Table 2) summarizes the characteristics
that influence cellular fate and that can drive tumori-
genic processes.
Conclusions
Regulation of translation is crucial for cell proliferation
and cell fate in human malignancies. There is increasing
evidence that epitranscriptional modifications affect
translation by modifying the affinity or the stability of
mRNAs, tRNAs, or the interactions between them inside
the ribosome.
Here, we have reviewed the various modifications of
transfer and ribosomal RNAs that are known to have
consequences for translation in human cancer (Fig. 2).
We chose to exclude modifications affecting other types
of RNAs and alterations in the expression and activity of
specific translation factors, not only because these have
already been extensively reviewed [106, 107], but also to
present a consistent overview of the role of RNA modifi-
cations in the core functions of translation.
The role of epigenetics in cancer is now very firmly
established, to the extent that corresponding therapies
exist. However, the recent expansion of our knowledge
about epitranscriptomics has not yet resulted in any
clinical applications, although there is evidence of prog-
nostic markers and possible treatments. In this sense,
the exhaustive characterization and classification of
RNA modifiers in each relevant cell type as tumor sup-
pressor or oncogene will provide us with tools to identify
new targets and design specific treatments that disrupt
the carcinogenic pathways [108, 109]. Certainly, it is very
important to identify the cellular background, as for a
specific cancer type, different environments can be bene-
ficial or lead to apoptosis [110].
Studies highlight that fibrillarin is frequently overex-
pressed in human cancer, and its expression controls the
fine-tuning of ribose 2′-O-methylation of the rRNA in
human cancer. FBL depletion leads to the regulation of
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IRES translation globally, but some specific mRNAs are
altered in a different way, such as p53, whose expression
increases when FBL is knocked down, and also revealed
by ribosome profiling [21]. Further studies would cer-
tainly confirm the qualitative and quantitative role of
FBL in human cancer translation and would produce
substantial information about identifying the down-
stream molecular and cellular functions affected by this
mechanism. Cellular context is a critical factor as a
stress influence on the translational response to FBL
modulation [21]. Clinically, fibrillarin has not yet been
exploited as an oncological target, but a recent review
emphasizes its potential as a therapeutic target that
could lower the genotoxic effects of anti-cancer treat-
ment. This could be achieved by exploiting the associ-
ation between low levels of FBL expression and better
breast cancer survival, and its functions in ribosome bio-
genesis and p53 regulation [111]. Other 2′-O-methyla-
tion modifiers have shown therapeutic potential, such as
SNORD44 in colorectal cancer and SNORD47 in glio-
blastoma [112, 113].
Few studies have highlighted the relevance of dyskerin
in driving cancer development. Their findings can ex-
plain in part the increased risk of cancer observed in X-
Fig. 2 Schematic representation of translational effects triggered by RNA modification defects at rRNA and tRNA in the context of cancer cells
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DC. In some other studies, the translational impact of
pseudouridylation defects is not clear. This is the case
for SNORA42 in lung cancer [10], in which SNORA42 is
overexpressed in non-small cell lung cancer and its sup-
pression inhibits cell growth, proliferation and tumori-
genicity of cancer cells by inducing p53-dependent
apoptosis. These results were partially confirmed 2 years
later [114], but a translational shift driven by SNORA42
remains to be conclusively demonstrated. Strikingly, Bel-
lodi et al., found that SNORA42 expression is increased
in DKC1(ΔL37)-mutated lymphocytes, which raises the
possibility that certain snoRNAs may be selectively in-
creased as a compensatory mechanism for perturbations
in subsets of H/ACA snoRNAs [115]. They also ob-
served an unexpected heterogeneity of expression of the
H/ACA snoRNAs in cells of patients with X-DC harbor-
ing distinct DKC1 mutations. This is in line with the un-
expected 2′-O-methylation alteration observed in X-DC.
Very recently, a study linked the rRNA 2′-O-methyla-
tion alteration caused by NPM1 mutations to the devel-
opment of congenital dyskeratosis [116]. These results
demonstrate the complex etiology of such diseases and
how a common phenotype can arise as the result of dif-
ferent alterations.
Modifications can directly influence the level of tRNAs
by modulating their stability. The by-products formed
by angiogenin cleavage regulate translation in human
cancer. There are many examples in the literature of ef-
forts that have been made to improve our understanding
of the subtle influence of proteomic modifications and
the consequent tumorigenesis. Another aspect emerging
from these studies is the difficulty of appreciating the
enzyme-site-specific role. Indeed, this is the case for
ribosomal RNA modifiers also, lots of enzymes have a
panel of activities, and the modulation of its expression
can have side effects that also play a role in translational
changes. For example, TRIT1 and ALKBH8 functions
are deeply related as mcm5U have been described as i6A
dependent, although they are described as a tumor sup-
pressor and oncogene respectively, some hypotheses
exist as other functions of the genes but more research
are needed to clarify it. This is also the case for NSUN5,
we related the translational changes to the modification
on the rRNA as it logically seems to have the most dir-
ect role on ribosome function. Nevertheless, considering
the clinical implications of these modifiers, it is certain
that the global phenotype takes precedence over the sin-
gle modification. A nuance is the relevance of a cancer-
specific translation in drug development and therapeutic
opportunities [117]. For example, in 1990, the discovery
that eIF4E overexpression could drive tumor initiation
has led to the development of strategies to decrease its
expression. To go further, ribosomal RNA modifications
can lead to antibiotic resistance in yeast, so antibiotic-
like drugs could specifically target the altered RNAs in
cancer. In this regard, in 2013 Begley and colleagues found
that tRNA methyltransferase 9-like protein (hTRM9L)
was downregulated in breast, bladder, colorectal, cervix
and testicular carcinomas and this downregulation was as-
sociated with altered tRNA modification levels [118]. Im-
portantly, hTRM9L-deficient tumors were highly sensitive
to aminoglycoside antibiotics [118]. Regarding tRNAs,
NSUN2 overexpression indicates a shorter overall survival
in head and neck carcinomas [32]. Another example is
ALKBH8, which is crucial in bladder cancer transform-
ation. It has been proposed that an intravesical injection
of ALKBH8 siRNA may reverse the invasive character of
the neoplasm in patients [38, 98]. It has also been de-
scribed that a deficit of ALKBH8 increases the sensitivity
to DNA-damaging agents and could complement the pre-
vious strategy [38]. Moreover, Rapino et al. proposed that
targeting wobble uridine 34 (U34) tRNA (U34 enzymes)
can avoid the resistance to Vemurafenib in BRAFV600E
melanoma [41].
RNA modifications have a promising future. The rela-
tively small number of studies, whether considering
tRNA or rRNA, that completely describe the transla-
tional role of a specific modification in this context high-
lights the significant gap that remains to be filled if we
are to better understand the complex mechanism of
tumorigenesis (Fig. 1; Tables 1 and 2). In this puzzle, the
addition or removal of a piece (RNA modifications) can
effectively change the final picture.
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